financetom
Business
financetom
/
Business
/
OpenAI rolls out assistant-like feature 'Tasks' to take on Alexa, Siri
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
OpenAI rolls out assistant-like feature 'Tasks' to take on Alexa, Siri
Jan 14, 2025 10:17 AM

Jan 14 (Reuters) - Generative artificial intelligence

bellwether OpenAI said on Tuesday that it is introducing a beta

feature called Tasks to ChatGPT, signaling the company's foray

into the virtual assistant space, competing with Apple's ( AAPL )

Siri and Amazon's ( AMZN ) Alexa.

Tasks will enable ChatGPT users to request tasks to be

performed at a future time, including one-time reminders such as

concert ticket sales or recurring actions like weekly news

briefings or daily weather updates.

Based on user chats, ChatGPT may also suggest tasks,

although users will have the option to accept or decline them.

The release of ChatGPT in late 2022 sparked a frenzy of

investment in AI firms, prompting Amazon ( AMZN ) to update its

decade-old, money-losing Alexa service with GenAI capabilities

to remain competitive with GenAI-powered chatbots.

In December last year, Amazon ( AMZN ) CEO Andy Jassy said that the

revamped version of Alexa-which will take actions for users

without prompting-is slated to be released in the "coming

months".

Meanwhile, Apple ( AAPL ) has

integrated

its "Apple Intelligence" technology into Siri, leveraging

ChatGPT's expertise and seeking permission from users before

querying the OpenAI service as part of Apple's ( AAPL ) tie-up with the

Microsoft ( MSFT )-backed startup.

OpenAI said that it will start rolling out the beta to

Plus, Team, and Pro users globally over the next few days,

beginning with the web platform.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Akamai Technologies Insider Sold Shares Worth $265,020, According to a Recent SEC Filing
Akamai Technologies Insider Sold Shares Worth $265,020, According to a Recent SEC Filing
Jun 14, 2024
05:41 PM EDT, 06/14/2024 (MT Newswires) -- Robert Blumofe, Chief Technology Officer, on June 14, 2024, sold 3,000 shares in Akamai Technologies ( AKAM ) for $265,020. Following the Form 4 filing with the SEC, Blumofe has control over a total of 24,729 shares of the company, with 24,729 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1086222/000108622224000180/xslF345X03/wk-form4_1718401044.xml Price: 89.17, Change: +0.08, Percent...
Apparel retailer Express Inc's bankruptcy buyout gets court approval
Apparel retailer Express Inc's bankruptcy buyout gets court approval
Jun 14, 2024
June 14 (Reuters) - Phoenix Retail, a new online retailing venture, will acquire most assets of Express Inc ( EXPRQ ), a court document showed, less than two months after the apparel retailer filed for bankruptcy. Phoenix, a joint venture among equity investor WHP Global and mall owners Simon Property Group ( SPG ) and Brookfield Properties, on Friday received...
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
Jun 14, 2024
(Reuters) - The U.S Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a September hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy. (Reporting by Puyaan Singh in Bengaluru) ...
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
Jun 14, 2024
June 14 (Reuters) - The U.S Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a September hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy. (Reporting by Puyaan Singh in Bengaluru) ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved